Efficacy and Safety of Everolimus with Reduced Tacrolimus in Living-Donor Liver Transplant (LDLT) Recipients with Hepatocellular Carcinoma: Subgroup Analysis from the H2307 Study

被引：0
|
作者：
Jeng, L. -B. [1 ]
Lee, S. -G. [2 ]
Lee, W. -C. [3 ]
Suh, K. -S. [4 ]
Joo, D. J. [5 ]
Joh, J. [6 ]
Kaido, T. [7 ]
Lopez, P. [8 ]
Kochuparampil, J. [8 ]
Kaneko, S. [9 ]
Levy, G. [10 ]
机构：
[1] China Med Univ Hosp, Taichung, Taiwan
[2] Asan Med Ctr, Seoul, South Korea
[3] Chang Gung Mem Hosp, Taoyuan, Taiwan
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Yonsei Univ, Coll Med, Severance Hosp, Seoul, South Korea
[6] Samsung Med Ctr, Seoul, South Korea
[7] Kyoto Univ Hosp, Kyoto, Japan
[8] Novartis Pharma AG, Basel, Switzerland
[9] Novartis Pharma KK, Tokyo, Japan
[10] Univ Toronto, Toronto, ON, Canada
来源：
TRANSPLANTATION | 2017年 / 101卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
LB P-19
引用
收藏
页码：375 / 376
页数：2
相关论文
共 50 条
  • [31] Post Hoc Subgroup Analysis of ZEUS: Outcome On Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion From a Calcineurin Inhibitor to an Everolimus Based Regimen
    Lehner, F.
    Sommerer, C.
    Arns, W.
    Reinke, P.
    Eisenberger, U.
    Wuthrich, R.
    Pressmar, K.
    Hauser, I.
    Porstner, M.
    May, C.
    Paulus, E.
    Muehlfeld, A.
    Suwelack, B.
    Wolters, H.
    Witzke, O.
    Stahl, R.
    Budde, K.
    TRANSPLANTATION, 2014, 98 : 613 - 613
  • [32] Post Hoc Subgroup Analysis of ZEUS: Outcome On Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion From a Calcineurin Inhibitor to an Everolimus Based Regimen
    Lehner, F.
    Sommerer, C.
    Arns, W.
    Reinke, P.
    Eisenberger, U.
    Wuthrich, R.
    Pressmar, K.
    Hauser, I.
    Porstner, M.
    May, C.
    Paulus, E.
    Muehlfeld, A.
    Suwelack, B.
    Wolters, H.
    Witzke, O.
    Stahl, R.
    Budde, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 613 - 613
  • [33] POST HOC SUBGROUP ANALYSIS FROM ZEUS: OUTCOME ON RENAL FUNCTION, EFFICACY AND SAFETY IN LIVING-DONOR KIDNEY TRANSPLANT RECIPIENTS AFTER CONVERSION FROM A CALCINEURIN INHIBITOR TO AN EVEROLIMUS BASED REGIMEN
    Lehner, F.
    Sommerer, C.
    Arns, W.
    Reinke, P.
    Eisenberger, U.
    Wuethrich, R. P.
    Pressmar, K.
    Porstner, M.
    May, C.
    Paulus, E. -M.
    Muehlfeld, A.
    Wolters, H. H.
    Witzke, O.
    Stahl, R. O.
    Budde, K.
    TRANSPLANT INTERNATIONAL, 2013, 26 : 8 - 8
  • [34] A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients
    Zhengshan Wu
    Qingyang Meng
    Yongxiang Xia
    Feng Zhang
    Wei You
    The Journal of Biomedical Research, 2013, 27 (04) : 305 - 309
  • [35] A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients
    Wu, Zhengshan
    Meng, Qingyang
    Xia, Yongxiang
    Zhang, Feng
    You, Wei
    JOURNAL OF BIOMEDICAL RESEARCH, 2013, 27 (04): : 305 - 309
  • [36] Efficacy and safety of everolimus in combination with reduced tacrolimus in de novo liver transplant recipients: 36-month results from the randomized H2304 study
    Saliba, Faouzi
    Kaiser, Gernot M.
    De Carlis, Luciano
    Metselaar, Herold J.
    De Simone, Paolo
    Duvoux, Christophe
    Nevens, Frederik
    Fischer, Lutz
    Fung, John J.
    Dong, Gaohong
    Rauer, Barbara
    Junge, Guido
    HEPATOLOGY, 2013, 58 (06) : 1383A - 1383A
  • [37] EFFICACY AND SAFETY OF EVEROLIMUS IN COMBINATION WITH REDUCED TACROLIMUS IN DE NOVO LIVER TRANSPLANT RECIPIENTS: 36-MONTH RESULTS FROM THE RANDOMIZED H2304 STUDY
    Saliba, F.
    Duvoux, C.
    Durand, F.
    Neau-Cransac, M.
    Hardwigsen, J.
    Pageaux, G.
    Di Giambattista, F.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 18 - 18
  • [38] The H2304E1 Study: Efficacy and Safety of Everolimus With Reduced Tacrolimus Versus Standard Tacrolimus in De Novo Liver Transplant Recipients at 36 Months.
    De Simone, P.
    Kaiser, G. M.
    De Carlis, L.
    Metselaar, H. J.
    Duvoux, C.
    Nevens, F.
    Fischer, L.
    Fung, J.
    Dong, G.
    Rauer, B.
    Junge, G.
    Saliba, F.
    LIVER TRANSPLANTATION, 2014, 20 : S106 - S106
  • [39] EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED TACROLIMUS IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS: DESIGN AND BASELINE CHARACTERISTICS OF CRADLE STUDY
    Martins, S.
    Pape, L.
    Toenshoff, B.
    Dello Strologo, L.
    Ettenger, R.
    Martzloff, D.
    Lopez, P.
    Vergara, M.
    Ng, J.
    PEDIATRIC TRANSPLANTATION, 2015, 19 : 70 - 70
  • [40] mTOR Inhibition with Everolimus in De Novo Living Donor Liver Transplantation-24-Months Results from the H2307 Pivotal Trial.
    Jeng, L.
    Lee, S.
    Soin, A.
    Uemoto, S.
    Maluf, D.
    Emond, J.
    Meier, M.
    Kochuparampil, J.
    Sips, C.
    Kaneko, S.
    Levy, G.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 269 - 269
12345